Introduction
p53 is one of the major determinants of antiproliferative response that integrates multiple stress signals to ensure against abnormal cell growth and tumorigenesis. In the last decade, multiple studies have highlighted the important role of p53 in differentiation of adult tissues as well. p53 has been found to suppress white adipocyte differentiation program by independent groups [1] [2] [3] . These studies convincingly show negative influence of p53 on PPAR-gamma expression in adipocytes. PPAR-gamma has been entitled as the master regulator of adipogenesis in consideration of its essential nature in the differentiation process. In agreement with negative regulation of white adipogenesis, p53 has been found to protect against diet-induced obesity in mice, which also involves its regulatory function in metabolism [3] . In this study, the p53 knockout mice were found to exhibit higher body fat acquisition compared to wild-type mice when fed with high-fat diet. Moreover, the genetically obese mice show higher expression of p53 at RNA level in adipose tissue in the fed state condition with concomitant activation of downstream genes [4] . In this context, overexpression of p53 in ob/ob mice suppressed lipogenic gene signature in response to refeeding via repression of SREBP-1c (sterol regulatory element-binding protein-1c) gene in adipose tissue. Thus, p53 is believed to function to ensure against excess fat accumulation in adipose tissue and manifestation of obesity. Another study, on a similar metabolic relevance shows that upregulation of p53 can lead to insulin resistance in adipose tissue of mice with dietary obesity, which could be improved by inhibition of p53 [5] .
Despite evidences proving p53 as a negative regulator of adipocyte differentiation, the mechanistic details on molecular functions of p53 have not been elucidated yet. It is known that activation of p53 leads to reduced expression of key adipogenic genes such as PPAR-gamma, but the nature of regulation of transcription, for example, direct or indirect have not been addressed before. Here, we report a previously unknown axis of transcriptional regulation exerted by p53 on CARM1 gene in the context of adipocyte differentiation process. CARM1 (Coactivator-associated arginine methyltransferase 1) is an important coactivator of transcription known for its proadipogenic functions. In this study, we show that p53 inhibits adipogenesis partly via suppression of expression of CARM1, a finding that seems to uncover the missing link that would explain mechanistically the antiadipogenic function of p53 as a regulator of transcription.
p53 and CARM1 are known to exert opposite functions in several cellular processes. It has been shown that ectopic overexpression of p53 could lead to spontaneous differentiation of hESCs (human embryonic stem cells) independently of Retinoic acid. Mechanistically, it was found that p53 can negatively regulate the expression of genes necessary for the maintenance of pluripotency such as Oct4, Sox2, Nanog, etc., [6] and through the activation of miR-145 and miR-34 which could target Oct4, Sox2, Klf4 etc. [7] . As CARM1 is also involved in the maintenance of pluripotency and its depletion has been found to lead to downregulation of pluripotent genes resulting in differentiation [8] , we speculated that p53 could also be a regulator of CARM1 expression in this context. Moreover, CARM1 has been convincingly shown to promote adipocyte differentiation as a bona fide coactivator of peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated gene regulation [9] . A comprehensive analysis of gene expression has unraveled a set of genes involved in lipid metabolism to be underrepresented in CARM1 knockout mouse embryos compared to wild-type control. In agreement to this finding, CARM1 knockout embryos showed reduced brown fat mass compared to wild-type counterparts. Additionally, CARM1-deficient cells exhibited lesser adipogenesis potential in terms of their conversion into mature adipocytes; further confirming its importance in regulating adipogenesis [9] . The functional antagonism existing between p53 and CARM1 in different physiological contexts such as maintenance of pluripotency, adipogenesis, and skeletal muscle differentiation prompted us to investigate the inter-relationship between p53 and CARM1 in terms of gene regulation.
Results

p53 negatively regulates CARM1 gene expression
To examine the possibility of p53-mediated regulation of CARM1 expression, the upstream regulatory elements of CARM1 gene was analyzed. Interestingly, the putative promoter sequence spanning 1.6 kb upstream of CARM1 gene was predicted to harbor two p53-binding sites by Consite bioinformatic tool with a 70% cutoff threshold value (Fig. 1A) . A comparison of consensus sequence for p53-mediated repression with that of the predicted p53-binding site on CARM1 promoter has been shown in Fig. 1B . Ectopic overexpression of FLAG-p53 was found to significantly repress CARM1 promoter-driven luciferase gene expression in H1299 p53
À/À cells, as evident from dose-dependent inhibitory activity (Fig. 1C) . In order to regulate CARM1 expression at transcriptional level, p53 must bind to CARM1 promoter as a prerequisite step. To assess the binding affinity of WT-p53 to the predicted DNA elements, Electrophoretic Mobility Shift Assay (EMSA) was performed with 32 P radiolableled oligos and bacterially expressed recombinant FLAG-p53. The results showed definitive interaction of p53 with the CARM1 promoter in vitro for both the putative binding sites (Lanes 1-3 of Fig. 1D,E) . To further confirm the specificity of the interaction, cold competition as well as supershift EMSA was performed. In cold competition EMSA, the addition of unlabeled target oligos in increasing doses resulted in decreased band intensity for the complex in a dosedependent manner; suggesting specificity of the probe for p53 binding (Lanes 4-8 of Fig. 1D,E) . Furthermore, in the presence of monoclonal p53 antibody a super-shifted band appeared that ran slower to the p53-DNA complex, indicating formation of AbProtein-DNA complex (Lanes 9-12 of Fig. 1D and Lane 14 of Fig. 1E ). ChIP assay was performed to assess the in vivo enrichment status of p53 on CARM1 promoter in H1299 p53
À/À cells with ectopic overexpression of WT-p53. ChIP-qPCR with pulled DNA showed around threefold enrichment of p53 on BS1 of CARM1 promoter in comparison to IgG control (Fig. 1F) . However, p53 enrichment status seemed to be negligible on BS2 of CARM1 promoter in comparison to IgG control. In this experiment, p21 promoter was considered as a positive control for p53 enrichment in vivo.
The observation that p53 can bind to CARM1 promoter and suppress CARM1 promoter-driven luciferase reporter expression, led us to investigate the effect of p53 in regulating endogenous CARM1 gene expression. Both RNA expression analysis by qRT-PCR and protein expression analysis by immunoblotting showed reduction in CARM1 levels with overexpression of WT-p53 in H1299 p53 À/À cells ( Fig. 2A,B) . Similar experiments were carried out in HCT116 p53 +/+ cells, . ChIP-qPCR result confirmed greater pull down of responsive DNA elements on CARM1 and p21 promoter with p53 antibody in comparison to IgG (Data: mean AE SD; n = 2; two-tailed unpaired Student's t-test; *P < 0.05, **P < 0.01, ns: not significant).
where p53 was activated via treatment with DNA damaging agent 5 0 FU (375 lM) in a time-dependent manner. Indeed p53 activation in HCT116 p53 +/+ cells led to concomitant reduction in CARM1 expression both at RNA and protein levels indicating negative regulation by p53 (Fig. 2C,D) . In this context, HCT116 p53
À/À cells did not show significant alteration in CARM1 expression upon 5 0 FU (375 lM) treatment (Fig. 2E,F) , indicating that the observed effect is due to p53 activation rather than any other DNA damage signaling. Collectively, these data suggest that CARM1 is a p53-responsive gene, where p53 negatively regulates CARM1 expression.
p53 inhibits adipogenesis and negatively regulates CARM1 expression in 3T3L1 cells
Previous studies have established a negative regulatory role for p53 in the context of adipogenesis [1] [2] [3] . However, on the contrary, CARM1 promotes the process of adipogenesis [9, 10] . In the present study, the finding on the negative transcriptional regulation of CARM1 by p53 seemed to be in perfect agreement with the previous observations on the functional antagonism observed between p53 and CARM1. At this stage it was imperative to probe into the cellular and physiological significance of p53-mediated regulation of CARM1 expression; which led us to examine the validity as well as implications of the above-mentioned regulatory axis in the context of adipocyte differentiation. 3T3L1 preadipocyte cell line has been used as a model system to study functional relevance of both p53 [1] [2] [3] and CARM1 [9] before. We performed gene expression analysis for CARM1 and p53 during the course of adipogenesis. CARM1 and PPARgamma expression seemed to have increasing trend through the course of adipogenesis (Fig. 3A ,B and C). However, p53 protein level showed initial increase followed by decrease through the course of differentiation up to Day 8 ( Fig. 3C ) in agreement with previous literature [1] . As differentiation is induced and facilitated with the help of IBMX, Dexamethasone, and Insulin, activation of other signaling pathways would compound the subsequent read out of gene regulation and an inverse correlationship between p53 and CARM1 expression may not be observed in all the time points. Nutlin-3a-mediated activation of p53 was found to inhibit adipocyte differentiation in 3T3L1 cells along with reduction in expression of PPAR-gamma (Fig. 4A ,B and C), conforming to the results of previous studies carried out by other groups. When gene expression analysis was performed for CARM1, both RNA as well as protein levels of CARM1 were found to be suppressed upon nutlin-3a treatment (Fig. 4D,E) ; indicating negative regulation of transcription by p53. In this context, p21 expression was taken as a positive control for p53-mediated gene regulation (Fig. 4F) . In our study, we have found 25 lM concentration of Nutlin-3a treatment to be suitable for downstream investigation, as higher concentration resulted in cell death and lower concentration did not effectively suppress CARM1 expression ( Fig. 5A-E) . Additionally, the effect of nutlin-3a treatment on expression status of CARM1 was analyzed at two time points (Day 3 and Day 6 along with Day 0) through adipogenesis process. Effective suppression of CARM1 as well as PPAR-gamma expression was observed (Fig. 6A ,B and C). We also performed similar experiments with p53 overexpression to corroborate the results obtained with nutlin3a experiment. p53 overexpression with transient transfection reduced adipogenesis as estimated by Oil Red O quantitation (Fig. 7A,B) . p53 overexpression also reduced expression of CARM1 at RNA and protein level (Fig. 7C,D) .
The mouse CARM1 promoter shares very little sequence conservation with human CARM1 promoter (around 30%; data not shown). However, the bioinformatic analysis with Consite tool predicted two p53-binding sites on mouse CARM1 promoter with 70% cutoff value (Fig. 7E) . Moreover, ChIP assay results clearly indicated enrichment of p53 on mouse CARM1 promoter majorly on BS1 (Fig. 7F) . Taken together, these data suggest that CARM1 is a p53-responsive gene in adipocytes, where p53 can suppress CARM1 expression in 3T3L1 cells. mean AE SD; n = 2; two-tailed unpaired Student's t-test; *P < 0.05, ***P < 0.001). (B) qRT-PCR to analyze CARM1 expression at RNA level through the course of differentiation (D0, D3, D6) (Data: mean AE SD; n = 2; two-tailed unpaired Student's t-test; *P < 0.05) (C) Immunoblotting to analyze p53 and CARM1 expression at protein level through the course of differentiation (D0, D2, D4, D6, D8). CARM1 shows increment in expression with the progression of adipogenesis, while p53 showed increment from D0 to D2 followed by decrease in subsequent stages of adipogenesis (Data represent two independent experiments).
Overexpression of CARM1 enhances adipocyte differentiation in 3T3L1 cells
Previous studies on CARM1 knockout mice and CARM1 knockdown by shRNA in 3T3L1 cells have shown that adipogenesis is impaired in the absence of CARM1 [9] . In agreement with these results we observed enhanced adipogenesis upon ectopic overexpression of CARM1 in 3T3-L1 preadipocytes with concomitant enhancement in expression of PPAR-gamma ( Fig. 8A-E) .
With myriads of transcriptional targets, p53 is believed to negatively regulate adipogenesis via multiple pathways, which are yet to be determined. In this study, we wanted to verify whether p53 suppresses adipogenesis via repression of CARM1 gene expression. To probe into the possibility of p53-CARM1 regulatory axis being one of the mechanisms operating to suppress adipocyte differentiation, a rescue experiment was performed, with simultaneous overexpression of CARM1 by transfection and activation of p53 via nutlin-3a treatment. Overexpression of CARM1 seemed to improve overall adipogenesis and rescue inhibitory effect of nutlin-3a on adipocyte differentiation (Fig. 8F,G) . The results of rescue experiment suggests that p53-CARM1 axis of gene regulation could be one of the mechanisms (if not the sole mechanism) that explains the inhibitory effect of p53 on adipogenesis.
Transcriptomics analysis in 3T3L1 cells with activation of p53: implication in CARM1 expression, thereby adipogenesis
The molecular functions of p53 in regulating adipocyte differentiation program are less characterized compared to other differentiation models. Although a few genes have been shown to negatively respond to activation of p53 in adipocytes such as PPAR-gamma, aP2, etc., the mechanistic details of regulation are yet to be addressed. Direct transcriptional targets of p53 having relevance in adipogenesis process are still undetermined. The limited knowledge on regulatory role of p53 during adipogenesis necessitated a high-throughput transcriptome analysis for better understanding on gene profile influenced by p53. For this purpose 3T3L1 preadipocyte cells were treated with Nutlin-3a (25 lM) for 24 h and total RNA was isolated and subjected to illumina-based total RNA sequencing. Of 470 differentially expressed genes, 286 genes showed upregulation and 184 genes showed downregulation with log2FC threshold of 2. The heat map of gene cluster showing differential expression relative to the median expression has been shown in Fig. 9A . Further functional annotation of the modulated genes unraveled multiple biological pathways to be affected by p53 when activated by nutlin-3a treatment such as p53 signaling pathway, Rho signaling pathway, ATF-2 transcription network, cellular differentiation, and metabolism of lipids and lipoproteins etc. The pathways were shortlisted on the basis of their relevance and significance and were combined to generate an interlinked molecular network (Fig. 9B) . The network modeling revealed several important features in terms of biological pathways modulated by p53 for future studies. In the context of white adipocyte differentiation process, p53 suppressed PPAR-gamma expression that confirmed the qRT-PCR analysis performed in Fig. 4C . p53 also activated expression of two positive regulators of adipogenesis, for example, C/EBPalpha and C/EBP-delta evidenced from RNA-seq; which seems to be counterintuitive in the light of inhibitory role of p53 in regulating adipogenesis. PPAR-gamma is ascribed as the master regulator of adipogenesis for the crucial role it plays during the process of adipocyte differentiation. However, the mechanism of regulation via which p53 leads to repression of PPAR-gamma is unknown at this stage. Interestingly, overexpression of CARM1 led to upregulated expression of PPAR-gamma in 3T3L1 preadipocytes as observed in Fig. 8C . Thus, it might be plausible to suggest that CARM1 is the intermediate regulator between p53 and PPAR-gamma. However, a similar assessment of expression of a few other adipogenesis-related genes such as GLUT4, Resistin, Leptin, etc., did not show antagonistic regulatory role of p53 and CARM1. A systematic transcriptomics analysis with modulation of CARM1 expression in 3T3L1 cells probably would reveal the array of commonly and reciprocally regulated genes in the context of adipogenesis. In order to further understand the role of CARM1 function in regulating expression and function of PPAR-gamma, a ChIP assay was performed with CARM1 antibody in 3T3L1 cells. CARM1 was found to be enriched on PPAR-gamma promoter, occupancy of which decreased upon nutlin-3a treatment (Fig. 9C ). This observation further indicates a role of CARM1 in contributing toward regulation of expression of PPARgamma. Moreover, CARM1 also showed definitive enrichment on the PPAR-gamma-responsive elements of FABP4/aP2 enhancer, which decreased with nutlin-3a treatment (Fig. 9D ). This result is indicative of coactivator function of CARM1 for PPAR-gamma-mediated regulation of expression of FABP4/aP2, which is in agreement with previous studies. However, it may not be possible to determine the relative contribution for CARM1 in regulating PPAR-gamma expression vs. its coactivator property for downstream regulations by PPAR-gamma, as CARM1 would rely on its coactivator property in order to regulate PPAR-gamma expression itself. To obtain further insight into the proposed p53-mediated repression of CARM1 expression, indeed functionally leading to inhibition of adipocyte differentiation phenotype, adipogenesis assay was performed with the inhibition of catalytic activity of CARM1 with the help of treatment with ellagic acid [10, 11] . Ellagic acid treatment at 25 lM concentration led to equivalent 
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001). (D) Immunoblotting to analyze protein expression of CARM1 upon exogenous overexpression of p53 via transfection in 3T3L1 cells for 24 h (Data represent two independent experiments). (E)
Schematic to show relative position of p53-binding sites on mouse CARM1 promoter as predicted by Consite with 70% cutoff threshold value. (F) ChIP-qPCR to assess enrichment status of p53 on mouse CARM1 promoter. Mouse p21 promoter was considered as the positive control (Data: mean AE SD; n = 2; two-tailed unpaired Student's t-test; *P < 0.05, **P < 0.01).
suppression of adipogenesis in comparison to p53 overexpression condition (Fig. 10A-C) . The combination of p53 overexpression and ellagic acid treatment did not reduce the extent of adipogenesis further, indicating that CARM1 suppression could be one of the major axes of regulation p53 could be relying on to inhibit adipogenesis.
Discussion
Regulation of CARM1 gene expression at post-transcriptional level has been studied by different groups and a few miRNAs such as miR181, miR223, miR15, and miR195 [12] [13] [14] [15] scenarios. However, transcriptional regulation of CARM1 gene has not been addressed yet. The CARM1 promoter is a TATA less promoter and is believed to allow dispersed transcription characteristics of housekeeping genes. In the present study, we identify CARM1 to be a p53-responsive gene, where p53 binds to CARM1 promoter as evident from EMSA and ChIP analysis, and negatively regulates expression of CARM1 in cell. The discrepancy between in vitro interaction and in vivo association of p53 at BS2 of CARM1 promoter could be because of proximity of the site to the transcription start site (TSS), as this region would be majorly occupied by basal transcription machinery thus eliminating chances of recruitment of the transcription factor p53.
To understand the physiological significance of p53-CARM1 axis of regulation, adipocyte differentiation model was taken into consideration, where both p53 and CARM1 show functional antagonism. Indeed in our assay system, overexpression or activation of p53 in 3T3L1 cells led to the inhibition of adipogenesis with concomitant repression of CARM1 expression. In this context, overexpression of CARM1 could enhance adipogenesis and rescue inhibitory effect of p53 on adipocyte differentiation process. Thus, p53-CARM1 axis of regulation seems to uphold in the context of adipogenesis, where p53 inhibits adipocyte differentiation partly via repression of CARM1 expression. Further transcriptomic analysis and gene network modeling revealed multiple pathways along with lipid biogenesis pathway to be modulated by p53 in 3T3L1 preadipocytes.
The experimental evidences on p53-mediated repression of CARM1 expression seem to bridge the mechanistic gap existing within the regulatory influence of p53 on PPAR-gamma expression in adipocytes. The master regulator of adipogenesis PPAR-gamma is negatively regulated by p53 and positively regulated by CARM1 at RNA level, which corroborates the known literature. However, the mechanistic details of the regulation have not been investigated yet. Previous studies by other groups show that inhibition of catalytic activity of CARM1 by ellagic acid also reduces PPARgamma expression resulting in lowered lipid accumulation in adipocytes; thus having promising implications in obesity management [10] . CARM1 is a known secondary coactivator for SRC-3 (steroid receptor coactivator-3) and SRC-3 has been shown to regulate PPARgamma expression in 3T3L1 preadipocytes [16] . Therefore, as a matter of logical assumption, CARM1 probably regulates PPAR-gamma expression via SRC-3 coactivator. Indeed CARM1 was found to be enriched on PPAR-gamma promoter; occupancy of which decreased with nutlin-3a treatment. Thus, p53-mediated suppression of PPAR-gamma could be speculated to occur via repression of CARM1 expression. With further validations, the newly identified p53-CARM1-PPAR-gamma regulatory axis would illuminate our understanding on metabolism of glucose and lipid at organismal level with a molecular basis and allow us to address obesity and associative complications such as diabetes with better scientific preparedness; where PPAR-gamma has been studied as a therapeutic target in the last decade. Further investigation would be necessary to determine the gene signature that is regulated by p53 via regulation of CARM1 expression, aside from PPAR-gamma. An investigation to elucidate the role of p53 in regulating newly identified pathways in adipocytes, aside from lipid biogenesis, would be necessary to understand the metabolic role of p53 comprehensively in the process of adipogenesis.
In the context of adipogenesis, CCAAT/enhancerbinding protein (C/EBP) family of proteins play equally important role to that of PPAR-gamma [17, 18] . C/EBP-d and C/EBP-b are expressed during early phases of adipogenesis and have been demonstrated to regulate PPAR-gamma expression [19] [20] [21] . On the other hand PPAR-gamma can activate expression of C/EBP-a during later stages of adipogenesis that regulates terminal differentiation [21] . Therefore, activation of C/EBP-a with nutlin-3a treatment seemed paradoxical in regard to its ultimate effect on adipogenesis. It would be interesting to further elucidate the relevance of such a regulation in recent future. There are multiple gene regulatory axes described before which involve p53-mediated gene regulation to inhibit the process of cellular differentiation. One such example is repression of myogenin expression by p53 to suppress muscle differentiation in response to genotoxic stress [22] . However, no direct targets of p53 have been documented in the context of adipogenesis. The p53-CARM1 axis uncovered in the present study provides an important mechanistic explanation for the p53-mediated suppression of adipogenesis for the first time. It would be also interesting to determine the functional status of p53-CARM1 regulatory axis in the context of cellular differentiation of other lineages, where p53 and CARM1 exhibit antagonistic functions such as muscle differentiation and myeloid differentiation. In case of muscle differentiation, p53 and CARM1 show similar functional behavior to that of adipogenesis. However, in the context of myeloid differentiation the regulatory influence of both the candidates are opposite in nature, that is, p53 favors where CARM1 suppresses myeloid differentiation [13, 23] .
Experimental procedures
Cell culture
All the mammalian cell lines used for the study were obtained from ATCC (American Type Culture Collection). HEK293T, HCT116, and 3T3L1 cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM), whereas H1299 cell line was grown in RPMI. In all cases the growth medium was supplemented with 10% FBS for cell culture irrespective of the cell line. Mammalian cell lines were grown in 37°C incubator with 5% CO 2 and 90% relative humidity.
Immunoblotting
Cells were lysed in laemmli buffer (1X: 2% SDS, 10% Glycerol, 62.5 mM Tris-Cl, pH 6.8) or RIPA buffer (1X: 50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 5 mM EDTA, pH 8.0, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS) and WCE were electrophoresed on 12% SDS/PAGE and transferred onto PVDF membrane (Merck Millipore, Burlington, MA, USA) in transfer buffer (25 mM Tris, 192 mM glycine, 0.036% SDS in 20% methanol) by Semidry transfer method. After blocking in 5% skimmed milk, the proteins of interest were detected with the help of their corresponding primary antibodies prepared in 1% skimmed milk or 1% BSA. HRP-conjugated secondary antibodies (Genei, Bangalore, India) were used against the primary antibodies to obtain a chemiluminescent signal in the presence of Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA), which was developed either by autoradiography on X-ray films or digital imaging system using Versa Doc.
Cloning of human CARM1 promoter
The desired promoter DNA sequence was amplified from genomic DNA using primers, harboring restriction sites for KpnI and XhoI (as specified in the Table S1 ). The PCR product (1473 bp; À1600 to À127) was used to clone the sequence in pGL3 basic vector using KpnI HF and XhoI restriction enzymes. The presence of cloned DNA in pGL3 reporter vector was confirmed by double digestion as well as sequencing.
Luciferase assay
H1299 cells were transfected with desired plasmids using lipofectamine 2000 reagent. Transfection was done in triplicates at 50% confluency state. pCMV b galactosidase plasmid was cotransfected as internal transfection control. After 24 h of transfection, cells were harvested and lysed using 1 9 luciferase reporter lysis buffer (Promega, Madison, WI, USA). Lysates were incubated with substrate luciferin in 1 : 1 ratio and photon emission of respective samples was recorded using Wallac scintillation counter. Counts were normalized against beta-galactosidase activity.
Purification of recombinant FLAG-p53
E. coli BL21 cells, transformed with bacterial expression vector of pET21b-FLAG-p53, were grown in LB medium and induced with 0.7 mM IPTG at cell density OD 600 of 0.7 and incubated for 5 h at 30°C. Cells pelleted and resuspended in BC300 and sonicated. After centrifugation at 30 000 g for 30 min at 4°C, supernatant was kept for binding with M2 agarose beads for overnight at 4°C. Beads were washed with BC300, then BC100 and then eluted with BC100 containing FLAG peptide (150 lgÁmL À1 ).
Electrophoretic mobility shift assay
Target DNA oligos from CARM1 promoter were end labeled with c 32 P ATP using T4 Polynucleotide kinase and isolated via Phenol-chloroform-isopropanol (PCI) extraction method. The labeled single-stranded DNA was annealed with equimolar amounts of complementary strand in annealing buffer (10 mM Tris-Cl, pH 8.0, 20 mM NaCl) and purified by passing through Sephadex C-50 column. The activity of radiolabeled probes was measured with the help of scintillation counter. Labeled oligos with 5000 cpm were incubated with respective recombinant proteins at 30°C for 30 min in EMSA buffer (25 mM HEPES pH 7.4, 50 mM KCl, 20% glycerol, 0.1% NP40) and complexes were resolved on 5% native PAGE (5% acrylamide: bisacrylamide (19 : 1) mix, 0.5 9 TBE, 0.1% APS, 0.03% TEMED) for 2 h at 4°C. Gel was dried and kept for exposure to X-ray films. Different DNA oligos taken for EMSA have been enlisted in Table S1 with their respective sequences.
Total RNA isolation
Cells were lysed with Trizol solution (Ambion Life Technologies). Chloroform was added to the sample (1/5 volume of trizol; for example, 0.2 mL to 1 mL) and mixed by shaking and inverting for 15 s followed by incubation at RT for 5 min. Samples were centrifuged at 16 200 g for 15 min at 4°C. The RNA containing aqueous phase was separated and added with equal volume of isopropanol and incubated at RT for 10 min. The samples were centrifuged at 16 200 g for 10 min at 4°C to precipitate RNA. The RNA pellet was washed with 75% ethanol and air-dried. The dried RNA pellet was dissolved in RNAase-free water, which was facilitated by incubation at 55°C for 10 min. The concentration of RNA was determined spectrophotometrically with the help of a nanodrop. The purified RNA was run on 1% agarose gel to assess quality of RNA where 28S rRNA and 18S rRNA appeared as two distinct bands in 2 : 1 ratio (the ratio showed variation across different cell lines). The RNA samples were stored in À80°C until further use.
Quantitative real-time PCR
In the case of RNA expression analysis, cDNA was synthesized from total RNA using MMLV reverse transcriptase (Sigma-Aldrich, St. Louis, MO, USA) in the presence of 0.5 mM dNTP and 3.5 lM oligo dT (Sigma-Aldrich) and was taken as template for amplification in qRT-PCR, considering different primer sets which target representative cDNAs for the mRNAs of different genes. For ChIP-qPCR experiment, the immuno-pulldown DNA was taken as the template for PCR amplification, using primers flanking the genomic region of interest. qRT-PCR amplification was done in kappa SYBR green reagent (Biosystems) (Initial denaturation for 10 min at 95°C; Cycles: 95°C 15″, 65°C for 30″, 72°C for 30″) with the help of real-time PCR instrument (Applied Biosystems). For estimation of relative fold change in RNA expression following calculation was followed: Relative fold change = 2 ÀDDCt ; where DDCt = DCt value of sample -DCt value of control and DCt = Ct value of target -Ct value of internal control, for example, actin for individual sample. In case of ChIP-QPCR experiment the following calculation was followed: Relative fold enrichment = 2 ÀDDCt ; where DDCt = DCt value for ab -DCt value for IgG and DCt = Ct value of sample (IgG/ab) -Ct value of 1% Input. The primer sequences used for qRT-PCR and ChIP-qPCR have been mentioned in Table S1 .
Chromatin Immunoprecipitation assay
H1299 p53
À/À and 3T3L1 preadipocyte cells were transfected with pCMV-p53 plasmid for 24 h or 3T3L1 cells were treated with nutlin-3a at 25 lM concentration for 24 h. Cells were washed with PBS for 5 min. Then crosslinking of chromatin was done using 1% formaldehyde solution. Cells were lysed with SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM TrisCl, pH8.0) and lysates were sonicated to shear genomic DNA to lengths between 100 and 500 bps. At this stage, a fraction of sonicated chromatin was separated as input. Sonicated chromatin was incubated with preblocked Protein G agarose beads for 1 h at 4°C. Centrifuged and supernatant was incubated with immunoprecipitating antibody p53 or CARM1 for overnight at 4°C on end to end rotor. The immuno-complex was precipitated using preblocked Protein G agaorse beads. After washes with low-salt buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-Cl pH 8.0, 2 mM EDTA, 150 mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-Cl pH 8.0, 2 mM EDTA, 500 mM NaCl), and LiCl buffer (0.25M LiCl, 1% NP40, 1% Sodium deoxycholate, 1 mM EDTA, 10 mM Tris-Cl pH 8.0) and TE (10 mM Tris-Cl pH 8.0, 1 mM EDTA) histone complexes were eluted out using elution buffer (1%SDS, 0.1M NaHCO 3 ) at RT for 30 min. Supernatant was added with 20ul of 5M NaCl and reverse crosslinking was performed at 65°C for 4 h. At this stage input was processed and de-crosslinked. The de-crosslinked chromatin was treated with proteinase K and RNase A to degrade all the proteins and RNA in the samples. Then DNA was recovered using Phenol-chloroform-isoamyl alcohol (25 : 24 : 1) extraction and used for qPCR experiment.
Adipogenesis
3T3L1 preadipocytes were grown to confluency and 24 h postconfluent cells were incubated with differentiation medium (growth medium containing 1 lM Dexamethasone, 0.5 mM IBMX and 1 lgÁmL À1 insulin) for 2 days.
Then the cells were supplemented with maintenance medium (growth medium with 1 lgÁmL À1 insulin) every alternative day. On 8th day postinduction of differentiation, the cells were fixed with 3.7% formaldehyde solution followed by staining with Oil Red O dye (Sigma-Aldrich) (prepared in 60% isopropanol) for 1 h at RT. The representative images of the stained cells were recorded for further analysis and comparison. The incorporated dye was extracted using isopropanol and absorbance values were determined spectrophotometrically at 510 nm to estimate total amount of lipid accumulation under different experimental conditions.
Transcriptomics analysis by RNA-Seq
Total RNA was isolated from 3T3L1 cells under different treatment conditions, as described earlier. The quality and quantity of RNA was assessed spectrophotometrically by a Nanodrop (Nanodrop 1000, Thermo Scientific, Waltham, MA, USA) and Bioanalyzer. The total RNA was subjected to high-throughput sequencing with the help of illumina. The raw data obtained from illumina were processed for trimming followed by quality control (QC) assessment with the help of NGSQC toolkit v2.3.3. The high-quality (HQ) filtered files were taken forward for alignment to mouse mm10 genome with the help of TopHat, which tracks mRNAs with a splice-junction mapping approach. The accepted individual RNA-seq reads were assembled with the help of Cufflinks software. The assembled transcripts were merged with the help of Cuffmerger. The differential expression analysis was done with the help of Cuffdiff at a Log2 FC (fold change) cutoff value of 2 and P Value < = 0.05. GEO accession number for the RNA-seq data: GSE100811.
Reagents, plasmids, and antibodies 
Statistical analysis
All the statistical analyses were performed using GraphPad Prism 7 Software (California, USA). The data obtained from two to three independent experiments, as specified in individual figure legends, were expressed as mean AE SD. Either two-tailed unpaired Student's t-test or one-way ANOVA with Dunnett's multiple comparision was used to determine the statistical significance values. A P-value of equal to or less than 0.05 was considered statistically significant.
